Publications by authors named "Puneet Mohan"

Claim this Profile
A
Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy.
John D Horowitz, Raffaele De Caterina, Tamila Heresztyn, John H Alexander, Ulrika Andersson, Puneet Mohan

J Am Coll Cardiol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial.
Jan H Cornel, Renato D Lopes, Stefan James, Susanna R Stevens, Megan L Neely, Puneet Mohan

Am Heart J· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.
Michael S Hanna, Puneet Mohan, Robert Knabb, Elora Gupta, Charles Frost

Ann N Y Acad Sci· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Greg Flaker, Renato D Lopes, Sana M Al-Khatib, Antonio G Hermosillo, Stefan H Hohnloser, Puneet Mohan

J Am Coll Cardiol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Ziad Hijazi, Agneta Siegbahn, Ulrika Andersson, Christopher B Granger, John H Alexander, Puneet Mohan

Circulation· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Renato D Lopes, Sana M Al-Khatib, Lars Wallentin, Hongqiu Yang, Jack Ansell, Puneet Mohan

Lancet· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
J Donald Easton, Renato D Lopes, M Cecilia Bahit, Daniel M Wojdyla, Christopher B Granger, Puneet Mohan

Lancet Neurol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban versus warfarin in patients with atrial fibrillation.
Christopher B Granger, John H Alexander, John J V McMurray, Renato D Lopes, Elaine M Hylek, Puneet Mohan

N Engl J Med· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor.
Richard C Becker, Hongqiu Yang, Yuchen Barrett, Puneet Mohan, Jessie Wang

J Thromb Thrombolysis· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban with antiplatelet therapy after acute coronary syndrome.
John H Alexander, Renato D Lopes, Stefan James, Rakhi Kilaru, Yaohua He, Puneet Mohan

N Engl J Med· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Yu Chen Barrett, Jessie Wang, Robert Knabb, Puneet Mohan

Thromb Haemost· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Richard C Becker, John H Alexander, L Kristin Newby, Hongqiu Yang, Yuchen Barrett, Puneet Mohan

Thromb Haemost· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

Circulation· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis